Tanaproget
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Tanaproget (INN; developmental code names NSP-989, WAY-166989) is an investigational nonsteroidal progestin. It is a high affinity, high efficacy, and very selective agonist of the progesterone receptor (PR). Due to its much more selective binding profile relative to most conventional, steroidal progestins, tanaproget may prove to produce fewer side effects in comparison. As of December 2010, it is in phase II clinical trials in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. An analog of tanaproget, 4-fluoropropyltanaproget ( 18 F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.
Tanaproget (INN; developmental code names NSP-989, WAY-166989) is an investigational nonsteroidal progestin. It is a high affinity, high efficacy, and very selective agonist of the progesterone receptor (PR). Due to its much more selective binding profile relative to most conventional, steroidal progestins, tanaproget may prove to produce fewer side effects in comparison. As of December 2010, it is in phase II clinical trials in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. An analog of tanaproget, 4-fluoropropyltanaproget ( 18 F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.
See also
Finerenone Mapracorat Prinaberel
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329039615 under CC BY-SA 4.0; modifications have been made.